Concepedia

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

Jeanne S. Geiser, Michael Heathman, Xuewei Cui, Jennifer A. Martin, Corina Loghin, Jenny Y. Chien, Amparo de la Peña

Clinical Pharmacokinetics · 2015 · 101 citations · 8 references

DOI

Concepts

References

8

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Carol Wysham, Thomas Blevins, Richard F. Arakaki et al. · Diabetes Care · 2014 · 387 citations

, , +17

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Guillermo E. Umpierrez, Federico Pérez Manghi, Linda Shurzinske et al. · Diabetes Care · 2014 · 337 citations

, , +17

Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

Wolfgang Glaesner, Andrew Vick, Rohn Millican et al. · Diabetes/Metabolism Research and Reviews · 2010 · 295 citations

, , +17

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Michael A. Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez et al. · Diabetes Care · 2014 · 280 citations · Full text

, , +17

A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

Peggy L. Barrington, Jenny Y. Chien, H. D. Hollis Showalter et al. · Diabetes Obesity and Metabolism · 2011 · 120 citations

, , +17